What is Humanetics?
Humanetics Corporation is dedicated to the accelerated discovery, development, and commercialization of proprietary drugs. The company's strategic focus lies in addressing markets with urgent and unmet medical needs, particularly in the areas of medical countermeasures and radiation modulators for oncology and inflammatory lung diseases. This specialized approach targets critical therapeutic areas where innovative pharmaceutical solutions are paramount.
How much funding has Humanetics raised?
Humanetics has raised a total of $5M across 1 funding round:
Other Financing Round
$5M
Other Financing Round (2024): $5M with participation from U.S. Department of Defense
Key Investors in Humanetics
U.S. Department of Defense
The U.S. Department of Defense is the federal department responsible for national security and the United States Armed Forces. Founded in 1947, it oversees defense policy, military operations, and the development of advanced security technologies, playing a crucial role in supporting critical research and development initiatives.
What's next for Humanetics?
With this recent major strategic investment, Humanetics is poised to significantly advance its pipeline and operational capabilities. The enterprise-level backing suggests a strategic focus on achieving key development milestones, potentially including expanded clinical trials, regulatory submissions, and the scaling of manufacturing processes. The company's trajectory indicates a strong emphasis on translating its research into tangible therapeutic solutions for complex medical conditions, reinforcing its role in the pharmaceutical innovation landscape.
See full Humanetics company page
